Fig. 1: The workflow of pancreatic cancer patients and healthy control participants for developing and evaluating prediction models.

a All the 425 serum samples, including 213 pancreatic cancer patients from 14 hospitals and 212 healthy controls without cancer from three clinics, were randomly divided into the training and validation cohorts.